Bio/Pharma Business

San Antonio, TX (Nov. 1)-The opening session of the ?Pharmaceutical Technologies? track at the 2006 Annual Meeting of the American Association of Pharmaceutical Scientists in San Antonio, Texas was standing room only as R. Christian Moreton, PhD, vice-president of pharmaceutical science at Idenix Pharmaceuticals, and Richard O. Mannion of Purdue Pharma discussed ?Product Development Using a Virtual Company Model.?

Mid-size regional players have little chance for success in an industry increasingly dominated by large global players.

Mid-size regional players have little chance for success in an industry increasingly dominated by large global players.

More CMOs look to proprietary delivery technologies to enhance profitability.

New York, NY (Oct. 19)-Pfizer, Inc. plans to implement a new company-wide cost-cutting initiative in 2007 as part of strategy to improve operating performance. The cuts are in addition to a previous cost-reduction program that Pfizer launched in 2005.

Langley, BC, Canada (Oct. 10)-AnorMED Inc. has determined that Genzyme's US $580 million offer to acquire all outstanding AnorMED shares at US $13.50 a share is a "superior proposal."

CPhI Worldwide, Paris (Oct. 3)-Exhibitors at CPhI Worldwide reported expansions, enhancements in technology, and new projects last week in Paris.

Kevin Sharer has become chairman of the board of the Pharmaceutical Research and Manufacturers of America upon the resignation of Peter R. Dolan.

Merck KGaA has agreed to buy a majority stake in the European biotechnology company Serono SA for CHF 16.6 billion ($13.3 billion).

Chemir Analytical Services has launched IQsynthesis, formerly known as Gateway Chemical Technology, Inc. Chemir acquired Gateway Chemical Technology, which provides custom synthesis and process development services, in May 2006.

Mid-size companies are forcing through their market positions by developing their niche competencies and their flexibilities to be recognized as serious market contenders.

The overall market size of the Southeast Asia region totals $7 billion, with a projected compound annual growth rate of about 13% through 2010.

For once, casting originators against generic players might end up strengthening the industry across the board.

Contract service providers should be concerned about the market perceptions of their performance.

The principal objective of the annual PharmSource–Pharmaceutical Technology outsourcing survey is to gauge overall business trends in the contract manufacturing and research businesses. This year's edition documents an industry that is in good health but facing a new set of dynamics.

Pharmaceutical Technology provides perspective on pharmaceutical manufacturing activity, assessing the product portfolios, prescription volumes, revenues, and capital spending plans of more than 500 drug-makers. Novartis leads in diversity, with 889 products; Pfizer leads in number of scrips (352 million) and revenue ($44 billion). And generics companies are coming up on the inside.

The laboratory supplier landscape is undergoing a radical makeover.

Cambrex Reports Loss; Advances Biosciences Business

The big question for pharmaceutical services providers coming into 2006 is: will the good times continue to roll?

From politics to paychecks and downsizings to deadlines-what it's like to work for one of the world's largest industries.

Pfizer to Shut Parsippany Plant

Contract services providers gained a valuable look into major market conditions, offshoring trends, and 2006 growth opportunities during a morning presentation entitled "CMC Sourcing in transition: Consolidation, Offshoring, and the Market Outlook," presented by Jim Miller. Miller is president of PharmSource (Springfield, VA, www.pharmsource.com), publisher of the Bio/Pharmaceutical Outsourcing , and contributing editor of Pharmaceutical Technology.

Roche Puts Hold on Tamiflu in US

Novartis Purchases Chiron in a Total Buyout

Biogen to Cut Jobs

MGI Pharma To Buy Guilford

Teva Absorbs Ivax In $7.4 Billion Bid

Aptuit To Purchase Quintiles

Able Labs Files for Chapter 11

Xanodyne Acquires aaiPharma Assets